Home > Boards > US Listed > Biotechs > Oncolytics Biotech Inc (ONCY)
Followed By 82
Posts 11244
Boards Moderated 0
Alias Born 11/02/2003

Friday, February 26, 2021 7:20:32 AM

Re: None

Post# of 210
NEWS -- Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full-Year Financial Results and Operational Highlights

Conference call and webcast to take place on Friday, March 5, 2021 at 8:30 am ET

SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 2021, at 8:30 am ET to discuss a corporate update and financial results for the fourth quarter and full year 2020.

Conference Call & Webcast

Date: Friday, March 5, 2021
Time: 8:30 am ET
Dial In – North American Toll-Free: (888) 231-8191
Dial In – International: (647) 427-7450
Conference ID (if needed): 569-6653
Webcast: https://produceredition.webcasts.com/starthere.jsp?ei=1432035&tp_key=48e3f6e8b0

A live webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking https://ir.oncolyticsbiotech.com/events-presentations and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (855) 859-2056 (North America) or (416) 849-0833 (International) and using reference code: 569-6653.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements, including the Company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic, the company's intentions regarding a potential phase 3 study involving pelareorep; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Company Contact

Kirk Look
Chief Financial Officer
+1-403-670-7658
mailto://KLook@oncolytics.ca

Investor Relations for Oncolytics

Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com

View original content: http://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-operational-highlights-301236150.html

SOURCE Oncolytics Biotech® Inc.
Recent ONCY News

FEATURED Goldshore Resources Announces Public (NSERC & MITACS) and Educational (Lakehead University) Tri-Party Institutional Partnership with Alliance Grant May 25, 2022 8:20 AM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Agrees Terms With an Acquisition Delivering Upwards of $100 Million in Annual Revenue ILUS May 25, 2022 11:52 AM

Branded Legacy, Inc. To Introduce New Delta 9 blend THC-0/Delta-8 Blend Gummies Sell Out Again BLEG May 25, 2022 8:30 AM

Ultrack Systems Fully Acquires California Trucking Company M-Loan Inc. MJLB May 24, 2022 9:30 AM

SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment CMND May 24, 2022 8:36 AM

PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America PSYC May 24, 2022 8:30 AM

Splash Beverage Group Broadens Reach through Agreement with Maryland's Buck Distributing SBEV May 24, 2022 8:12 AM

Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022 EMED May 24, 2022 6:00 AM

HPIL HOLDING (OTC: HPIL) SETTLES ANOTHER LAWSUIT HPIL May 23, 2022 4:30 PM

A.I.S. Resources Identifies Prospective Drill Targets at Reliance Reef and Provides Bright Gold Project Update AIS May 20, 2022 8:00 AM

Lomiko Announces Commencement of Exploration Drilling for its La Loutre Graphite Project LMR May 19, 2022 10:56 AM

PTOP Announces MOBICARD ™ 2.0 Development Contract has been executed PTOP May 19, 2022 10:00 AM

Edison Lithium Spin-Out of Cobalt Assets EDDYF May 19, 2022 8:00 AM

Goldshore Resources Announces Innovative Technology Application for Moss Lake Project Exploration and Closing of Non-Brokered Financing GSHRF May 19, 2022 8:00 AM

Demand Brands kicks off cultivation at Corralitos Farms DMAN May 18, 2022 2:00 PM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y